Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer [0.03%]
三阴性乳腺癌病理发生发展的进展研究
Yuhan Liu,Yuhan Zou,Yangli Ye et al.
Yuhan Liu et al.
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by high aggressiveness, high malignancy, and poor prognosis compared to other breast cancer subtypes. ...
Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial [0.03%]
晚期肺癌患者以护士为主的筛查启动早期专业姑息治疗项目：一项多中心随机对照试验
Yoshihisa Matsumoto,Shigeki Umemura,Ayumi Okizaki et al.
Yoshihisa Matsumoto et al.
Background: We aimed to examine the effectiveness of a nurse-led, screening-triggered early specialized palliative care intervention program for patients with advanced lung cancer. ...
Randomized Controlled Trial
Cancer medicine. 2024 Nov;13(22):e70325. DOI:10.1002/cam4.70325 2024
Machine Learning Models to Predict Bone Metastasis Risk in Patients With Lung Cancer [0.03%]
用于预测肺癌患者骨转移风险的机器学习模型
Kevin Wang Leong So,Evan Mang Ching Leung,Tommy Ng et al.
Kevin Wang Leong So et al.
Introduction: The aim of this study was to find the most appropriate variables to input into machine learning algorithms to identify those patients with primary lung malignancy with high risk for metastasis to the bone. ...
Cost-Effectiveness Analysis of Adjuvant Alectinib versus Platinum-Based Chemotherapy in Resected ALK-Positive Non-Small-Cell Lung Cancer in the Chinese Health Care System [0.03%]
克唑替尼序贯化疗 vs 阿来替尼辅助治疗亚洲ALK阳性完全切除的Ⅱ~ⅢB期NSCLC患者的成本效益分析
Qiran Wei,Yifang Liang,Jiahui Mao et al.
Qiran Wei et al.
Objectives: The ALINE trial demonstrated the superiority of alectinib over platinum-based chemotherapy in resected Anaplastic Lymphoma Kinase (ALK)-positive non-small-cell lung cancer (NSCLC). Considering the high cost of...
Comparative Study
Cancer medicine. 2024 Nov;13(22):e70405. DOI:10.1002/cam4.70405 2024
Establishment of a Novel Risk Stratification System Integrating Clinical and Pathological Parameters for Prognostication and Clinical Decision-Making in Early-Stage Cervical Cancer [0.03%]
基于临床和病理参数的新型风险分层系统在早期宫颈癌预后及临床决策中的建立
Haiying Wu,Lin Huang,Xiangtong Chen et al.
Haiying Wu et al.
Background: Highly heterogeneity and inconsistency in terms of prognosis are widely identified for early-stage cervical cancer (esCC). Herein, we aim to investigate for an intuitional risk stratification model for better ...
Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma [0.03%]
新辅助治疗与可切除胰腺导管腺癌初期手术的长期结局比较研究
Kyung In Shin,Min Sung Yoon,Jee Hoon Kim et al.
Kyung In Shin et al.
Introduction: This study aimed to compare the long-term effects of neoadjuvant therapy and upfront surgery on overall survival (OS) and progression-free survival (PFS) in patients with resectable pancreatic ductal adenoca...
Comparative Study
Cancer medicine. 2024 Nov;13(22):e70363. DOI:10.1002/cam4.70363 2024
Calcium Channel Blocker Versus Renin-Angiotensin System Inhibitor in Risk of Kidney Cancer Among Patients With Hypertension: A Propensity Score-Matched Cohort Study [0.03%]
高血压患者中钙通道阻滞剂与肾素血管紧张素系统抑制剂的肾脏癌风险：倾向性评分匹配队列研究
Minji Jung,Shufeng Li,Zhengyi Deng et al.
Minji Jung et al.
Background: Use of antihypertensive medications could be associated with an increased risk of kidney cancer. Despite their various mechanisms of action, whether this association differs between different classes of medica...
Comparative Study
Cancer medicine. 2024 Nov;13(22):e70429. DOI:10.1002/cam4.70429 2024
Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard Abstraction [0.03%]
与国际公认标准对比的犹他州全员理赔数据库在乳腺癌患者化疗和放疗剂量记录上的表现研究
Alzina Koric,Chun-Pin Esther Chang,Shane Lloyd et al.
Alzina Koric et al.
Objective: To evaluate the validity of the Utah statewide All-Payer Claims Database (APCD), we compared breast cancer-specific treatments and dosages with gold-standard abstraction of medical records. ...
Comparative Study
Cancer medicine. 2024 Nov;13(22):e70411. DOI:10.1002/cam4.70411 2024
Establishment and Validation of a Prognostic Nomogram for Predicting Postoperative Overall Survival in Advanced Stage III-IV Colorectal Cancer Patients [0.03%]
三期和四期结直肠癌患者术后预后预测 nomogram 的建立及验证
Pengwei Lou,Dongmei Luo,Yuting Huang et al.
Pengwei Lou et al.
Background: Most colorectal cancer (CRC) patients are at an advanced stage when they are first diagnosed. Risk factors for predicting overall survival (OS) in advanced stage CRC patients are crucial, and constructing a pr...